Prevalence of diabetic nephropathy and chronic kidney disease in diabetes mellitus in Russian Federation
- 作者: Maslova OV1, Suntsov Y.I1, Shestakova MV1, Kazakov IV1, Vikulova LK1, Sukhareva OY.1, Martynov SA1, Maslova OV1, Suntsov Y.I1, Shestakova MV1, Kazakova IV1, Vikulova LK1, Sukhareva OY.1, Martynov SA1
-
隶属关系:
- 期: 编号 3 (2010)
- 页面: 45-50
- 栏目: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245895
- ID: 245895
如何引用文章
全文:
详细
Materials and Methods: In 20 regions of Russia, 7174 patients with type 1 and type 2 diabetes mellitus were examined. Laboratory examination included measurement of HbA1c level, blood creatinine, urea, and CL levels, albumin excretion in a spot urine sample, BP measurement, and examination of the ocular fundus. The concentration of albumin in spot urine sample of 20 mg/l to 200 mg/l was considered as a MAU, above 200 mg/l - as PU. GFR was calculated by Cockcroft-Gault formula. Statistical analysis of results of the study was performed using STATISTICA 6 software. The data are presented as median and 25th and 75th percentiles (Me [25%, 75%]). Values of P<0.05 were considered statistically significant for all measurements.
Results: The actual prevalence of DN was 40.1% (type 1 DM) and 39.3% (type 2 DM), reportable prevalence - 28.8% and 8.7%, respectively. Pathological urinary albumin excretion was observed in 42% of patients with type 1 DM and in 46,2% of patients with type 2 DM. The prevalence of this indicator was increased with patient age and duration of DM, as well as poor control of carbohydrate metabolism and blood pressure. The prevalence of CKD stages 2-3 was significantly higher in patients with type 2 DM than in patients with type 1 diabetes. Further examination for identification of causes of non-diabetic CKD is required in 15% (type 1 DM) and 41.2% (type 2 DM) patients with MAU and GFR <60 ml/min/1.73 m².
Conclusion: The annual screening can detect complications of diabetes mellitus at earlier stages. Compensation of carbohydrate metabolism and blood pressure in patients with diabetes mellitus inhibits the progression of DN.
作者简介
O Maslova
Yu Suntsov
M Shestakova
I Kazakov
L Vikulova
O Sukhareva
S Martynov
O Maslova
Yu Suntsov
M Shestakova
I Kazakova
L Vikulova
O Sukhareva
S Martynov
参考
- American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2007; 30 (Suppl. 1): 42-47.
- Donnelly R., Emslie-Smith A.M. et al. Vascular complications of diabetes. BMJ 2000; 15 (320):1062-1066.
- Centers for Disease Control and Prevention (CDC). Incidence of end-stage renal disease among persons with diabetes - United States, 1990-2002. MMWR Morb. Wkly. Rep. 2005; 54 (43):1097 - 1100.
- Lok C.E., Oliver M.J. еt al. The growing volume of diabetes-related dialysis: a population based study. Nephrol. Dial. Transplant 2004; 19 (12): 3098-3103.
- Patient Registration Committee, Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of 31 December 2003. Ther. Apher. Dial. 2005; 9 (6): 431 - 458.
- Martinez-Castelao A., De Alvaro F., Gorriz J.Z. Epidemiology of diabetic nephropathy in Spain. Kidney Int. 2005; 99: S. 20 - 24.
- NKF-K/DOKI clinical practice guidelines for chronic kidney diseases: evaluation, classification and stratification. Am. J. Ridney Dis. 2002; 39 (Suppl. 1): 17 - 31.
- Дедов И.И., Шестакова М.В. Сахарный диабет. М.: Универсум Паблишинг. 2003.
- American Diabetes Association. Standards of Medical Care in Diabetes - 2007. Diabetes Care. 2007; 30 (Suppl. 1): 4-41.
- The EURODIAB IDDM Complications Study/ Microvascular and acute complications in IDDM patient. Diabetologia 1994; 37(3):278 - 285.
- Manaviat M.R., Shoja M. Retinopathy and microalbuminuria in type II diabetic patients. BMC Ophthalmol 2004; 4: 9.
- Yeung V.T., Lee K.F., еt al. MicroAlbuminuria Prevalence Study (MAPS) in hypertensive type 2 diabetic patients in Hong Kong. Hong Kong Med. J. 2006; 12 (3): 185 - 190.
- Parving H-H., Lewis JB., еt al., DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global prespective. Kidney Int. 2006; 69 (11): 2057 - 2063.
- Cederholm J., Eliasson B., еt al. For the steering committee of the Swedish National Diabetes Register. Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes Research and Clinical Practice. 2005; 67: 258-266.
- Kibriya M.G., Mahtab H. Micro-vascular complications in type 2 diabetes in Bangladesh: The Diabcare-Asia, Bangladesh Project. Diabetes research clinical practice. 2000; 50 (Suppl.257):1068.
- Dowse G.K., Humphrey ARG., еt al. Prevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauririus. Am. J. Epidemiol. 1998; 147: 448 - 457.
- Leelawattana R., Pratipanawatr T., Bunnag P. еt al. Thailand diabetes registry project: prevalence of vascular complications in long-standing type 2 diabetes. J. Med. Assoc. Thai. 2006; 89 (Suppl. 1): 54 - 59.
- Gudbjornsdottir S., Cederholm J., et al. Result Report NDR 2005. Socialstyrelsen: Stockholm. 2006.
- Lim H.S., Chew W.L.S., еt al. Metabolic indices and complications in relation to duration of diabetes - Findings of the Diabcare-Asia (Singapore) Study. Diabetes research clinical practice. 2000; 50 (Suppl. 134): 548.
- Laffel LM, McGill JB, Gans DJ. The beneficial affect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria: North American Microalbuminuria Study Group. Am. J. Med. 1995; 99: 497-504. 21. Bakris GL, Wiliams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis. 2000; 36: 646-661.
- The Diabetes Control and Complications Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes control and Complications Trial. Kidney Int. 1995; 47: 1703-1720.
- UKPDS: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837-853.